AVAI BIO Financials
This page shows AVAI BIO (AVAI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing is carrying operations as cash burn, rising liabilities, and near-zero liquidity keep the business financially constrained.
In FY2026, financing inflows of$952K almost matched operating cash burn of-$1.01M . With year-end cash at only$23K , outside capital was mainly replacing cash consumed by operations rather than building a liquidity cushion, even after fresh funding.
The company’s working-capital position is extremely tight: FY2026 current assets were just
Share count climbed from 117.2M in FY2024 to 153.2M in FY2026, showing that new capital has repeatedly come through equity issuance instead of internally generated cash. But balance-sheet repair did not follow: negative equity widened from
Financial Health Signals
AVAI BIO does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
AVAI BIO passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 3 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
AVAI BIO reported a net loss of $1.7M while operations used $1.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
AVAI BIO's EBITDA was -$1.7M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 61.4% from the prior year.
AVAI BIO reported -$1.7M in net income in fiscal year 2026.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
Cash & Balance Sheet
AVAI BIO held $23K in cash as of fiscal year 2026; long-term debt is not reported for that period.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
Margins & Returns
None of these metrics is reported for fiscal year 2026.
Capital Allocation
AVAI BIO invested $15K in research and development in fiscal year 2026.
Not reported for fiscal year 2026.
Not reported for fiscal year 2026.
AVAI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $276K-44.7% | $500K-58.8% | $1.2M+492.9% | $205K | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | $317K-55.4% | $711K-42.3% | $1.2M+166.9% | $461K | $0 |
| Gross Profit | N/A | N/A | N/A | N/A | -$40K+80.8% | -$211K-1174.8% | -$17K+93.5% | -$256K | $0 |
| R&D Expenses | N/A | $15K | N/A | N/A | N/A | N/A | N/A | $27K | $0 |
| SG&A Expenses | N/A | $792K+3.9% | $762K-46.5% | $1.4M+506.3% | $235K-47.7% | $449K+118.9% | $205K-10.5% | $229K+193.2% | $78K |
| Operating Income | N/A | -$1.7M | N/A | N/A | -$349K-375.8% | $127K-58.1% | $302K+334.4% | $70K+189.0% | -$78K |
| Interest Expense | N/A | N/A | N/A | N/A | $276K-70.0% | $921K-24.1% | $1.2M+69.2% | $717K | N/A |
| Net Income | N/A | -$1.7M | N/A | N/A | -$349K-175.8% | -$127K+58.1% | -$302K-334.4% | -$70K+11.0% | -$78K |
Not reported in any period shown, so not listed: Income Tax, EPS (Diluted).
TTM is the trailing twelve months, Q2 FY2026 through Q1 FY2027, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AVAI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $573K+154.8% | $225K-30.2% | $322K+33.4% | $241K-46.9% | $455K-44.3% | $816K+94.4% | $420K+1275.9% | $31K |
| Current Assets | $89K-4.1% | $93K-19.8% | $116K+7.9% | $108K-67.5% | $331K-46.7% | $620K+318.1% | $148K+482.6% | $25K |
| Cash & Equivalents | $23K-71.4% | $81K+28744.5% | $281-99.7% | $107K+222.8% | $33K-44.9% | $60K+121.1% | $27K+26665.7% | $102 |
| Accounts Receivable | N/A | N/A | N/A | N/A | $4K-94.1% | $64K | N/A | N/A |
| Total Liabilities | $3.4M+89.4% | $1.8M0.0% | $1.8M+104.5% | $875K+1.7% | $860K-24.8% | $1.1M+149.9% | $458K+471.1% | $80K |
| Current Liabilities | $3.4M+89.4% | $1.8M0.0% | $1.8M+104.5% | $875K+1.7% | $860K-24.8% | $1.1M+149.9% | $458K+1399.4% | $31K |
| Total Equity | -$2.8M-80.0% | -$1.6M-6.6% | -$1.5M-131.6% | -$633K-56.1% | -$406K-23.9% | -$327K-768.8% | -$38K+24.0% | -$50K |
| Retained Earnings | -$5.9M-42.5% | -$4.1M-38.4% | -$3.0M-251.0% | -$848K-271.0% | $496K+34.3% | $369K+650.9% | -$67K+15.1% | -$79K |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
AVAI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.2M | -$1.0M | N/A | -$1.3M-2328.2% | -$54K-110.2% | $535K+2217.1% | $23K-82.3% | $131K+255.3% | -$84K |
| Investing Cash Flow | N/A | N/A | N/A | -$149K-344.6% | -$34K+0.6% | -$34K-57.8% | -$21K+92.1% | -$271K-2652.0% | -$10K |
| Financing Cash Flow | $1.3M | $952K | N/A | $1.4M+741.3% | $162K-65.8% | $474K+1263.3% | $35K-79.3% | $168K+89.8% | $88K |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q2 FY2026 through Q1 FY2027, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AVAI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | -14.6%+27.5pp | -42.2%-40.8pp | -1.4% | -125.2% | N/A |
| Operating Margin | N/A | N/A | N/A | -126.3% | 25.3%+0.4pp | 24.9%-9.1pp | 34.0% | N/A |
| Net Margin | N/A | N/A | N/A | -126.3% | -25.3%-0.4pp | -24.9%+9.1pp | -34.0% | N/A |
| Return on Assets | -305.5% | N/A | N/A | -144.5%-116.7pp | -27.8%+9.2pp | -37.0%-20.5pp | -16.6%+239.7pp | -256.3% |
| Current Ratio | 0.030.0x | 0.050.0x | 0.06-0.1x | 0.12-0.3x | 0.38-0.2x | 0.54+0.2x | 0.32-0.5x | 0.83 |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$2.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where AVAI BIO Ranks
Frequently Asked Questions
Is AVAI BIO profitable?
No, AVAI BIO (AVAI) reported a net income of -$1.7M in fiscal year 2026.
What is AVAI BIO's EBITDA?
AVAI BIO (AVAI) had EBITDA of -$1.7M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is AVAI BIO's operating cash flow?
AVAI BIO (AVAI) recorded an outflow of $1.0M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are AVAI BIO's total assets?
AVAI BIO (AVAI) had $573K in total assets as of fiscal year 2026, including both current and long-term assets.
How much does AVAI BIO spend on research and development?
AVAI BIO (AVAI) invested $15K in research and development during fiscal year 2026.
What is AVAI BIO's current ratio?
AVAI BIO (AVAI) had a current ratio of 0.03 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.
What is AVAI BIO's return on assets (ROA)?
AVAI BIO (AVAI) had a return on assets of -305.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is AVAI BIO's cash runway?
Based on fiscal year 2026 data, AVAI BIO (AVAI) had $23K in cash against an annual operating cash burn of $1.0M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is AVAI BIO's debt-to-equity ratio negative or not reported?
AVAI BIO (AVAI) has negative shareholder equity of -$2.8M as of fiscal year 2026, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is AVAI BIO's Piotroski F-Score?
AVAI BIO (AVAI) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are AVAI BIO's earnings high quality?
AVAI BIO (AVAI) reported a net loss of $1.7M while operations used $1.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.